Table 4.

Lung NSCLC: Nonsmall Cell Lung Cancer//SCLC: Small Cell Lung Cancer.

Year, Ref.	Findings
2004 306	Silibinin impeded invasion by inhibiting expression of uPA and MMP2 and enhancing expression of TIMP2.
2013 307	Silibinin meglumine impeded the epithelial–mesenchymal transition in EGFR mutant NSCLC cells.
2010 308	Silibinin decreased NSCLC cell growth through cell cycle arrest and decreased cell cycle modulators.
2011 309	Silymarin produced apoptosis in a highly metastatic lung cancer cell line through the mitochondrial caspase pathway.
2003 310	Silibinin inhibited growth and apoptosis in NSCLC and SCLC line cells in a dose-dependent manner.
2012 311	HDAC inhibitors in combination with silibinin showed enhanced antitumor activity in NSCLC cells. There was also increased transcription of p21 through higher acetylation of its promoter. The augmented p21 was responsible for proteasomal destruction of cyclin B1.
2013 312	EGFR-mutated lung cancer cells, resistant to erlotinib and overexpressing ALDH, were resensitized by silibinin.
2009 313 X	Treating a xenograft lung cancer mouse model with silibinin resulted in a decreased tumor size through decreased angiogenesis. HIF-1α was also decreased by silibinin.
2016 314	Through downregulation of STAT3, silibinin reinstated sensitivity to crizotinib therapy in ALK rearranged lung cancer.